PDGFRalpha: a new therapeutic target in the treatment of hepatocellular carcinoma?
- PMID: 19335066
- DOI: 10.1517/14728220902719233
PDGFRalpha: a new therapeutic target in the treatment of hepatocellular carcinoma?
Abstract
Background: Hepatocellular carcinoma (HCC) develops most often in a background of chronic inflammatory liver injury from viral infection or alcohol use. Most HCCs are diagnosed at a stage at which surgical resection is not feasible. Even in patients receiving surgery rates of recurrence and metastasis remain high. There are few effective HCC therapies and hence a need for novel, rational approaches to treatment. Platelet derived growth factor receptor-alpha (PDGFR-alpha) is involved in tumor angiogenesis and maintenance of the tumor microenvironment and has been implicated in development and metastasis of HCC.
Objective: To examine PDGFR-alpha as a target for therapy of HCC and explore opportunities and strategies for PDGFR-alpha inhibition.
Methods: A review of relevant literature.
Results/conclusions: Targeted inhibition of PDGFR-alpha is a rational strategy for prevention and therapy of HCC.
Similar articles
-
[Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma].Gastroenterol Hepatol. 2010 Dec;33(10):741-52. doi: 10.1016/j.gastrohep.2010.05.007. Epub 2010 Sep 18. Gastroenterol Hepatol. 2010. PMID: 20851505 Spanish. No abstract available.
-
Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation.Curr Cancer Drug Targets. 2011 Oct;11(8):944-53. doi: 10.2174/156800911797264716. Curr Cancer Drug Targets. 2011. PMID: 21834756
-
[Sorafenib for the treatment of HCC--the beginning of a new era in the treatment of HCC].Z Gastroenterol. 2009 Jan;47(1):55-60. doi: 10.1055/s-0028-1109067. Epub 2009 Jan 20. Z Gastroenterol. 2009. PMID: 19156592 Review. German.
-
Targeted agents and systemic therapy in hepatocellular carcinoma.Recent Results Cancer Res. 2013;190:225-46. doi: 10.1007/978-3-642-16037-0_15. Recent Results Cancer Res. 2013. PMID: 22941024 Review.
-
Management of hepatocellular carcinoma: beyond sorafenib.Curr Oncol Rep. 2012 Jun;14(3):257-66. doi: 10.1007/s11912-012-0233-0. Curr Oncol Rep. 2012. PMID: 22434314 Review.
Cited by
-
Diverse structures and antihepatoma effect of sesquiterpenoid dimers from Artemisia eriopoda by AKT/STAT signaling pathway.Signal Transduct Target Ther. 2023 Feb 15;8(1):64. doi: 10.1038/s41392-022-01267-6. Signal Transduct Target Ther. 2023. PMID: 36788208 Free PMC article. No abstract available.
-
Characterization and Targeting of Platelet-Derived Growth Factor Receptor alpha (PDGFRA) in Inflammatory Breast Cancer (IBC).Neoplasia. 2017 Jul;19(7):564-573. doi: 10.1016/j.neo.2017.03.002. Epub 2017 Jun 10. Neoplasia. 2017. PMID: 28609680 Free PMC article.
-
Noncanonical Cell Death Induction by Reassortant Reovirus.J Virol. 2020 Oct 27;94(22):e01613-20. doi: 10.1128/JVI.01613-20. Print 2020 Oct 27. J Virol. 2020. PMID: 32847857 Free PMC article.
-
Quantitative LC-MS/MS uncovers the regulatory role of autophagy in immune thrombocytopenia.Cancer Cell Int. 2021 Oct 18;21(1):548. doi: 10.1186/s12935-021-02249-4. Cancer Cell Int. 2021. PMID: 34663331 Free PMC article.
-
Overexpression of Platelet-Derived Growth Factor Receptor Α D842V Mutants Prevents Liver Regeneration and Chemically Induced Hepatocarcinogenesis via Inhibition of MET and EGFR.J Cancer. 2020 May 18;11(15):4614-4624. doi: 10.7150/jca.44492. eCollection 2020. J Cancer. 2020. PMID: 32489479 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
